Clinical Trial Update: Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating navtemadlin added to ruxolitinib in JAK inhibitor-naïve myelofibrosis patients with suboptimal response; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Post-essential Thrombocythemia Myelofibrosis
• Post-polycythemia Vera Myelofibrosis

Drugs mentioned

• Navtemadlin (navtemadlin)
• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Kartos Therapeutics, Inc. | Conditions: Myelofibrosis, Post-PV MF | Phase 3 | Status: RECRUITING